Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04150965 · ClinicalTrials.gov registry record · Phase 1
Immuno-Oncology Drugs Elotuzumab, Anti-LAG-3 and Anti-TIGIT
A Phase 1 study, sponsored by Multiple Myeloma Research Consortium.
- Terminated
- Registry status
- Phase 1
- Development phase
- 14
- Enrollment target
NCT04150965: Clinical Trial Phase 1 study, sponsored by Multiple Myeloma Research Consortium.
NCT04150965 is a Phase 1 study that was terminated before completion, run by Multiple Myeloma Research Consortium. The registered enrollment target is 14 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (77% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04150965, a Phase 1 study, was terminated before completion, sponsored by Multiple Myeloma Research Consortium.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 14 participants
- Enrollment target
Study Summary
This a Phase I/II randomized trial for patients with relapsed refractory Multiple Myeloma who have relapsed after treatment with prior therapies. The protocol is designed to evaluate two agents, Anti-LAG-3 and Anti-TIGIT, in order to understand their immunologic effects and safety both as single agents and in combination with pomalidomide and dexamethasone. In these arms, patients will be treated with either Anti-LAG-3 or Anti-TIGIT respectively for one cycle as single agent followed by the addition of pomalidomide and dexamethasone in combination for subsequent cycles. A third arm allows patients to be treated with the FDA approved combination of elotuzumab plus pomalidomide and dexamethsone as a control. This arm will thus allow a concurrent standard of care comparator for the experimental arms.
Primary Outcome
The overall response rate of the drug combination, in each Arm for RRMM, which is defined as the proportion of subjects who achieved a response (≥ VGPR).
Interventions
- DRUG Elotuzumab, pomalidomide, dexamethasone
- DRUG Anti-LAG-3
- DRUG Anti-LAG-3 + Pomalidimide + Dexamethasone
- DRUG Anti-TIGIT
- DRUG Anti-TIGIT + Pomalidimide + Dexamethasone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2020-07-10 |
| Est. Completion | 2024-08-30 |
| Phase | Phase 1 |
Why NCT04150965 stopped before completion
NCT04150965 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 14 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (77% lower).
The record links to 0 conditions, and to 5 interventions - of which Elotuzumab, pomalidomide, dexamethasone is the first listed.
NCT04150965 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04150965 about?
NCT04150965 is a clinical study titled "Immuno-Oncology Drugs Elotuzumab, Anti-LAG-3 and Anti-TIGIT". This a Phase I/II randomized trial for patients with relapsed refractory Multiple Myeloma who have relapsed after treatment with prior therapies. The protocol is designed to evaluate two agents, Anti-LAG-3 and Anti-TIGIT, in order to understand their immunologic effects and safety both as single age...
What is the current status of trial NCT04150965?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 14 participants. The study started on 2020-07-10. Estimated completion is 2024-08-30.
What interventions are being tested in trial NCT04150965?
The interventions under investigation include: Elotuzumab, pomalidomide, dexamethasone (DRUG), Anti-LAG-3 (DRUG), Anti-LAG-3 + Pomalidimide + Dexamethasone (DRUG), Anti-TIGIT (DRUG), Anti-TIGIT + Pomalidimide + Dexamethasone (DRUG).
Who is sponsoring clinical trial NCT04150965?
This trial is sponsored by Multiple Myeloma Research Consortium, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04150965's enrollment target sits among peer trials
14 1844th of 2000 higher than 154 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02523092 · 14 participants · Phase 4
Use of CXCL9 as a Biomarker of Acthar Efficacy
- NCT04263285 · 14 participants · NA
Treatment of Depression Post-SCI
- NCT04743271 · 14 participants · NA
Food and Circadian Timing
- NCT05065671 · 14 participants · Phase 1
Microbiome Derived Metabolism and Pharmacokinetics
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT06358040 · started 2026-10 · NA
Opioid Dispenser for Microdiscectomy/Laminectomy